Concepedia

Howard L. Kaufman

HL

Statistics

Publications

154

Citations

15.9K

H-Index

62

Active since

1987

Affiliations

Rutgers, The State University of New Jersey(Current)

Rutgers Cancer Institute

Rush University Medical Center

Massachusetts General Hospital

Columbia University

Howard L. Kaufman is an author at Rutgers, The State University of New Jersey specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1987–2024

154

Publications

154

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

, , +3

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber, David H. Lawson, Jon Richards et al. · New England Journal of Medicine · 2011 · 878 citations

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott et al. · JAMA Oncology · 2015 · 653 citations

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Neil Senzer, Howard L. Kaufman, Thomas Amatruda et al. · Journal of Clinical Oncology · 2009 · 607 citations · Full text

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Jason Chesney, Igor Puzanov, Frances A. Collichio et al. · Journal of Clinical Oncology · 2017 · 604 citations · Full text

1–5 of 154